Brolucizumab intravitreal injection in macular neovascularization type 1: VA, SD-OCT and OCTA parameters changes during a 16-weeks follow up.

Lisa Toto,Maria Ludovica Ruggeri,Rossella D'Aloisio,Chiara De Nicola, Chiara Trivigno,Luca Cerino,Guido Di Marzio,Marta Di Nicola,Annamaria Porreca,Rodolfo Mastropasqua

Ophthalmic research（2022）

引用 1|浏览7

暂无评分

摘要

Brolucizumab is efficient in reducing all retinal fluids during the loading phase and shows reduction of macular thickness, choroidal thickness, and PED height. Most eyes at disease activity assessment (75%) fall into 12 week-interval and the minority (25%) into the 8 week-interval.

查看译文

关键词

macular neovascularization type,intravitreal injection,octa parameters changes,sd-oct

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要